Introduction
============

Hypoglycemia occurs in an appreciable number of individuals with type 2 diabetes mellitus (T2DM) who are receiving antidiabetic therapy ([@ref-25]). Iatrogenic hypoglycemia induces not only complications but also a substantial medical expense related to hospitalization ([@ref-22]). Prevention of hypoglycemia in diabetes is therefore an integral component of treatment ([@ref-4]). Importantly, intervention for relevant risk factors may reduce severe hypoglycemia and enhance quality of life in people with T2DM.

Iatrogenic hypoglycemia is associated with clinical complications. Elderly people with recurrent hypoglycemia are at risk of cognitive impairment ([@ref-19]). Severe hypoglycemia also contributes to a higher incidence of cardiovascular event and mortality ([@ref-13]). Moreover, risk of traumatic injury is notably increased in patients who experience severe hypoglycemia ([@ref-16]).

Epidemiologic studies have identified several risk factors for hypoglycemia in people with T2DM. Stringent glycemic targets are closely linked to the incidence of hypoglycemia ([@ref-18]). In addition, severe hypoglycemia occurs more frequently in the elderly, presumably due to lack of symptom recognition ([@ref-1]). Studies have also implicated diabetes duration as a risk factor, as demonstrated by progressive deterioration of hypoglycemic counterregulatory mechanism in people with longstanding disease ([@ref-9]; [@ref-2]).

The body mass index (BMI), as defined by dividing the weight in kilograms by the square of the height in meters, may be an important but overlooked risk factor for severe hypoglycemia. People with T2DM who have a lower BMI are also likely to have lower hepatic glycogen stores and this can diminish the secretion of glucose counterregulatory hormones during hypoglycemia ([@ref-28]). Reduced counterregulatory hormones may compromise an individual's capacity to stabilize blood glucose level during fasting ([@ref-15]). Furthermore, lower BMI in elderly individuals may reflect underlying frailty ([@ref-17]), which impairs both the recognition of and behavioral defense against hypoglycemia.

This study investigates the relationship between BMI and plasma glucose concentration during iatrogenic hypoglycemia in people with T2DM.

Materials and Methods
=====================

This is a cross-sectional study conducted at Changhua Christian Hospital in central Taiwan. Individuals hospitalized at the Endocrinology ward from September 2011 to August 2017 were assessed for eligibility. Enrollment criteria were people above 20 years of age, with existing diagnosis of T2DM, a documented plasma glucose level ≤70 mg/dL ([@ref-8]), and acute cognitive impairment that required hospitalization.

Candidates were excluded if they had chronic infection, traumatic injury, acute cerebro- or cardiovascular event, organ failure, or whose hypoglycemia was considered independent of antidiabetic medications. Moreover, people with malignancy, eating disorders, and previous gastrointestinal surgery were ineligible. The study was approved by the Institutional Review Board of Changhua Christian Hospital (CCH IRB number: 171105). Written consent to participate in the study was provided by the patients' next of kin.

Participants were assigned to two equally sized subgroups according to their BMI. Specifically, lower BMI subgroup denotes individuals whose BMI fall within lower half of the study population, and vice versa. Blood tests were performed at hospitalization except for glycosylated hemoglobin A~1c~ (HbA~1c~), which was extracted from existing laboratory data prior to the hypoglycemic event. Serum HbA1c was measured by ion-exchange high-performance liquid chromatography using BioRad VARIANT™ II Turbo system. Serum biochemistry including glucose, creatinine, and potassium were measured by Beckman Coulter UniCel DxC 800 Synchron™ Clinical Systems (Beckman Coulter, Brea, CA, USA). The analytical precision for serum glucose is within 2 mg/dL. Prescription details were collected from electronic medical records. The enrollment process is illustrated in [Fig. 1](#fig-1){ref-type="fig"}.

![Enrollment process of the study.](peerj-06-4348-g001){#fig-1}

Demographic data between BMI subgroups were compared using Mann--Whitney U test for continuous variables and Pearson's *χ*^2^ test for categorical variables. The plasma glucose concentration, serum potassium, and length of hospital stay were compared using Mann--Whitney U test. Multivariate regression analysis was performed to identify predictors of plasma glucose level at hospitalization. A two-tailed *P* value of less than 0.05 indicated statistical significance. Analysis was performed using IBM SPSS version 22.0 (IBM SPSS Statistics for Windows, Armonk, NY, USA).

Results
=======

The study enrolled 107 participants with T2DM who were hospitalized due to severe iatrogenic hypoglycemia. As shown in [Table 1](#table-1){ref-type="table"}, demographic characteristics including age (76.5 ± 13.8 years vs. 73.8 ± 11.7 years, *P* = 0.172), preceding HbA~1c~ (6.7 ± 1.1% vs. 6.8 ± 1.3%, *P* = 0.52), duration of diabetes (7.6 ± 4.5 years vs. 9.3 ± 4.9 years, *P* = 0.051), and serum creatinine (1.6 ± 1.0 mg/dL vs. 1.9 ± 1.6 mg/dL, *P* = 0.336) were comparable between BMI subgroups. Moreover, the proportion of participants using antidiabetic medication commonly implicated in iatrogenic hypoglycemia, such as insulin (26% vs. 32%, *P* = 0.31) or sulfonylurea (65% vs. 64%, *P* = 0.55), were also similar.
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###### Demographic characteristics of the body mass index subgroups.
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  Variables                      Lower BMI (*n* = 54)   Higher BMI (*n* = 53)   *P* value
  ------------------------------ ---------------------- ----------------------- -----------
  Age (years)                    76.5 ± 13.8            73.8 ± 11.7             0.172
  Sex (Female)                   29 (54%)               29 (55%)                0.53
  BMI (kg/m^2^)                  20.1 ± 1.78            27.0 ± 3.90             \<0.001
  HbA~1c~ (%)                    6.7 ± 1.1              6.8 ± 1.3               0.52
  Creatinine (mg/dL)             1.60 ± 1.00            1.91 ± 1.63             0.336
  Duration of diabetes (years)   7.6 ± 4.5              9.3 ± 4.9               0.051
  Use of insulin                 14 (26%)               17 (32%)                0.31
  Use of sulfonylurea            35 (65%)               34 (64%)                0.55

**Notes.**

Data are expressed as mean with standard deviation for continuous variables and number (%) for categorical variables. Continuous variables were compared using the Mann--Whitney *U* test for independent samples.

BMIbody mass indexHbA~1c~glycated hemoglobin A~1c~

As demonstrated in [Table 2](#table-2){ref-type="table"}, participants with lower BMI harbored substantially reduced plasma glucose concentration compared to those with higher BMI during iatrogenic hypoglycemia (30.1 ± 9.6 mg/dL vs. 38.4 ± 12.3 mg/dL, *P* \< 0.001). Nonetheless, individuals with lower BMI did not have an appreciably longer length of stay compared to their higher weight counterparts (6.2 ± 4.6 days vs. 5.7 ± 4.0 days, *P* = 0.77). Furthermore, mean serum potassium levels were similar between subgroups (3.7 ± 0.9 meq/L vs. 3.9 ± 0.8 meq/L, *P* = 0.14).
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###### Clinical features of the body mass index subgroups.
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  Variables                              Lower BMI (*n* = 54)   Higher BMI (*n* = 53)   *P* value
  -------------------------------------- ---------------------- ----------------------- -----------
  Plasma glucose concentration (mg/dL)   30.1 ± 9.61            38.4 ± 12.3             \<0.001
  Length of stay (days)                  6.2 ± 4.6              5.7 ± 4.0               0.77
  Potassium (mEq/L)                      **3.7** ± **0.86**     **3.9** ± **0.80**      0.14

**Notes.**

Data are expressed as mean with standard deviation for continuous variables. Continuous variables were compared using the Mann--Whitney U test for independent samples.

BMIbody mass index

Multivariate regression analysis identified covariates that potentially influence the plasma glucose concentration at hospitalization. The standardized coefficient of each independent variable is listed in [Table 3](#table-3){ref-type="table"}. As can be seen, BMI was significantly related to plasma glucose concentration during iatrogenic hypoglycemia in people with T2DM (*β* coefficient: 0.72, *P* = 0.008) after adjusting for confounding variables.

10.7717/peerj.4348/table-3

###### Multivariate regression analysis of covariates associated with plasma glucose concentration during iatrogenic hypoglycemia.
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  Covariates                     *β* coefficient   *P* value
  ------------------------------ ----------------- -----------
  Age (years)                    0.014             0.88
  BMI (kg/m^2^)                  0.72              0.008
  HbA~1c~ (%)                    −1.18             0.26
  Creatinine (mg/dL)             −1.1              0.21
  Duration of diabetes (years)   −0.037            0.88

**Notes.**
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Discussion
==========

People with T2DM are vulnerable to the detrimental effect of hypoglycemia, which may become a limiting factor in antidiabetic therapy ([@ref-24]). Apart from requiring the assistance of caregivers, severe hypoglycemia also induces harmful cardiac arrhythmia and functional brain failure ([@ref-3]). Moreover, hypoglycemia-associated autonomic failure can impair the physiologic and behavioral defense against a subsequent hypoglycemic event ([@ref-5]; [@ref-6]).

The observation in this study that lower weight people with T2DM had reduced plasma glucose concentration during iatrogenic hypoglycemia may be attributable to attenuated glucose counterregulatory mechanisms. People with lower BMI, perhaps reflecting less availability of hepatic glycogen, may have diminished secretion of glucagon and epinephrine ([@ref-28]), resulting in inadequate hepatic glucose production during iatrogenic hypoglycemia. Furthermore, the effect of glucagon may be compromised in people with inadequate glycogen since this hormone raises blood glucose level through hepatic glycogenolysis ([@ref-20]).

Moreover, unintentional weight loss may reflect frailty and functional disability ([@ref-29]). In lower weight people, delayed recognition of hypoglycemia may partly explain their appreciably lower plasma glucose level at hospitalization. People with lower BMI may therefore have limited ability to counteract hypoglycemia due to reduced secretion of glucose counterregulatory hormones, as discussed previously, and functional disability that leads to hypoglycemic unawareness.

Adipose tissue modifies insulin sensitivity through the production of adipokines ([@ref-26]; [@ref-11]). Weight loss improves insulin sensitivity by decreasing free fatty acid mobilization and by changing adipokine profile in obesity ([@ref-23]; [@ref-12]). Moreover, intentional weight loss in T2DM correlates with lower fasting plasma glucose concentration ([@ref-27]). Weight loss is therefore an established risk factor for iatrogenic hypoglycemia in diabetes ([@ref-20]). In clinical practice, BMI may indirectly mirror an individual's insulin sensitivity and subsequent risk of hypoglycemia. Therefore, dynamic change in body weight during glycemic treatment may require a corresponding adjustment in therapeutic regimen.

Intriguingly, although participants with lower BMI harbored reduced plasma glucose level at hospitalization, length of stay and serum potassium level were similar to their higher BMI counterparts. In other words, hypoglycemia may not cause immediately perceivable complications. Nonetheless, plasma glucose level below 30 mg/dL has been linked to permanent brain injury in an animal model ([@ref-21]), and lower weight people in this study with a mean blood glucose close to this level were at risk of long-term neurologic damage.

Several implications arise from the study's finding that lower weight participants had reduced plasma glucose level during iatrogenic hypoglycemia. Hypoglycemia in diabetes involves a combination of therapeutic insulin excess and compromised physiologic defense ([@ref-5]; [@ref-6]). Appropriate dosing of antidiabetic medications, especially sulfonylurea and insulin ([@ref-14]), is prudent for people with lower BMI. Lower weight people may also benefit from less stringent treatment target, frequent self-monitoring of blood glucose (SMBG), and continuous glucose monitoring (CGM) to detect asymptomatic hypoglycemia ([@ref-7]). Nutritional support to increase hepatic glycogen in at risk individuals may enhance physiologic defense against more severe hypoglycemia ([@ref-10]). Moreover, since the glucose-raising efficacy of glucagon is unreliable in people with inadequate glycogen, an alternative method may be necessary to restore normoglycemia in underweight patients.

The design of this study has limitations. To be hospitalized for treatment, participants obviously circumvented lethal complications such as cardiac arrhythmia, which may lead to selection bias. Furthermore, participants may have initially received management for hypoglycemia at home, and blood tests at hospitalization may not reveal the lowest plasma glucose concentration. A longer observation time may be necessary to identify potential complications associated with severe hypoglycemia. Hypoglycemic risk may also relate to the dose of antidiabetic medications, which was not addressed by the study. Moreover, neither hepatic glycogen quantity nor counterregulatory hormone level was measured, both of which may influence the severity of iatrogenic hypoglycemia.

Conclusions
===========

Lower weight individuals with T2DM harbored reduced plasma glucose concentration during iatrogenic hypoglycemia. People with lower BMI may have compromised defense against iatrogenic hypoglycemia due to reduced secretion of counterregulatory hormones and functional disability. Appropriate dosing of antidiabetic medications, individualized treatment target, frequent SMBG and CGM technology may help avert more severe hypoglycemia in people with lower BMI. Ultimately, nutritional support to increase hepatic glycogen may defend lower weight patients against severe hypoglycemia.
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###### Dataset for the study population

###### 

Click here for additional data file.
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